Skip to main content
Clinical Trials/NCT04804787
NCT04804787
Completed
Not Applicable

Emotions Recognition in Multiple Sclerosis

Lille Catholic University1 site in 1 country101 target enrollmentJune 23, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Multiple Sclerosis
Sponsor
Lille Catholic University
Enrollment
101
Locations
1
Primary Endpoint
Emotion's intensity
Status
Completed
Last Updated
4 months ago

Overview

Brief Summary

Through this study, a group composed of multiple sclerosis patients will be compared to a healthy volunteers group to determine if the positive emotions recognitions is preserved in the first group.

Detailed Description

Different studies have highlighted the specific deficiency concerning emotions recognition in multiple sclerosis. Patients with multiple sclerosis are reported to have more difficulty recognising negative emotions, especially anger and fear. In this context, RECODE study has a twofold objective: * To determine whether the positive emotions recognition remains preserved by combining behavioural and neurophysiological measures (electrodermal activity). * To study this disorder's etiology through a comparison between a multiple sclerosis patient group and a control group (matched in sex, age, and education's level).

Registry
clinicaltrials.gov
Start Date
June 23, 2021
End Date
February 25, 2025
Last Updated
4 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Lille Catholic University
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Male or female between 18 and 55 years old.
  • Understand and able to express themselves in French.
  • EXPERIMENTAL GROUP :
  • Relapsing-remitting form (RRMS)
  • With an EDSS \< 4 (Expanded Disability Status Scale)
  • No significant motor, cerebellar or somatosensory disorders of the upper limbs or visual disorders (EDSS specific parameter \<2)
  • No flare-up in the last 6 weeks
  • No corticosteroids taken in the last 4 weeks
  • CONTROL GROUP :
  • Lack of global cognitive deterioration (according to Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) standards).

Exclusion Criteria

  • Persons with previous neurological pathologies, head trauma with loss of consciousness, psychiatric pathologies, serious general affections, perceptive or dysarthric disorders preventing verbal communication or reading,
  • People with sensory disorders (visual and auditory) that interfere with the performance of neuropsychological tests;
  • Treatment with psychotropic drugs (except benzodiazepines and hypnotics).
  • Refusal to participate after clear and fair information about the study.
  • Major persons under guardianship, under judicial protection, persons deprived of liberty.
  • Pregnant or breastfeeding women

Outcomes

Primary Outcomes

Emotion's intensity

Time Frame: Day 0

Through the emotion recognition test, the attendees will have to evaluate the emotion's intensity conveyed by the stimuli on a scale ranging from 1 (the emotion conveyed is not very intense) to 10 (the emotion conveyed is very intense).

Emotion's valence

Time Frame: Day 0

Through the emotion recognition test, the attendees will have to evaluate the emotion's valence conveyed by the stimuli on a scale ranging from 1 (the emotion conveyed is negative) to 10 (the emotion conveyed is positive).

Emotion recognition

Time Frame: Day 0

Comparison of the answers obtained to the recognition question "In your opinion what is the emotion conveyed by this extract/face" in both groupsThrough the emotion recognition test, the attendees will have to evaluate the emotion perceived among 6 basic emotions (anger, disgust, joy, fear, surprise, sadness) and 14 complex emotions (benevolence, disappointment, boredom, enthusiasm, mischief, pride, frustration, shame, hostility, worry, interest, jealousy, sorrow, sneakiness).

Certainty's degree of answers

Time Frame: Day 0

Certainty's degree of the attendees answers to the recognition question on a scale from 1 ("I am not at all certain of my answer") to 10 ("I am quite certain of my answer")

Secondary Outcomes

  • California Verbal Learning Test (CVLT)(Day 0)
  • Brief Visuo-spatial Memory Test (BVMT)(Day 0)
  • Trail Making test(Day 0)
  • State Trait Anxiety Inventory Y-B (STAI Y-B)(Day 0)
  • Beck Depression Inventory (BDI)(At the unique experimental session)
  • Dot Probe Task(Day 0)
  • Change in the electrodermal response during emotion recognition test(Day 0)
  • Stroop test(Day 0)
  • Symbol Digit Modalities Test (SDMT)(Day 0)
  • Verbal fluency test(Dat 0)
  • State Trait Anxiety Inventory Y-A (STAI Y-A)(Day 0)
  • Toronto Alexithymia Scale-20 (TAS-20)(Day 0)

Study Sites (1)

Loading locations...

Similar Trials